Protein growth factors as potential therapies for central nervous system demyelinative disorders.
Demyelinative diseases are frequently accompanied by loss of oligodendroglia; in such instances, oligodendroglial regeneration must precede remyelination. Recent studies indicate that extracellular proteins such as platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) profoundly influence the oligodendroglial lineage. PDGF stimulates the formation of oligodendroglia from partially differentiated progenitor cells, whereas bFGF induces mature oligodendroglia to proliferate and dedifferentiate. Manipulations of the central nervous system concentrations of these and other protein growth factors may prove of therapeutic value in multiple sclerosis.
Children's Hospital of Philadelphia, PA 19104.
J B
JB
Grinspan
J
J
Stern
B
B
Franceschini
T
T
Yasuda
D
D
Pleasure
D000328:Adult; D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D003711:Demyelinating Diseases / Q000188:drug therapy*; D005346:Fibroblast Growth Factors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D051379:Mice; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009416:Nerve Regeneration / Q000187:drug effects; D009836:Oligodendroglia / Q000187:drug effects / Q000502:physiology; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology / Q000627:therapeutic use*
D010982:Platelet-Derived Growth Factor; D005346:Fibroblast Growth Factors